Contact information
matthew.wood@paediatrics.ox.ac.uk
01865 272419
01865 282840
Louise Gillane
mjaw-pa@paediatrics.ox.ac.uk
Matthew Wood
Professor of Neuroscience
Matthew Wood graduated in Medicine from the University of Cape Town in 1987, working in clinical Neuroscience before gaining a doctorate in Physiological Sciences from the University of Oxford in 1993. He is currently University Lecturer, and Fellow and Tutor in Medicine and Physiology at Somerville College.
Matthew’s research is in field of gene therapy for degenerative disorders of the nervous system and muscle. The main focus is the investigation of novel therapeutic approaches utilising short nucleic acids to target messenger RNA. Targeting RNA has the potential to allow modification of the target transcript, reprogramming of endogenous genetic defects or the targeting of specific disease alleles, all the while maintaining endogenous regulation of the target gene. Current work is investigating the potential of single-stranded antisense oligonucleotides for the modification of mRNA splicing, for example in Duchenne muscular dystrophy. In addition, the potential of double-stranded RNA for gene silencing, known as RNA interference (RNAi), is being investigated for the silencing of target genes and mutant alleles both in muscle and in the nervous system. In particular, RNAi has great potential as a future therapeutic agent for currently untreatable neurodegenerative disorders such as Parkinson’s disease.
Recent publications
Targeted BDNF upregulation via upstream open reading frame disruption
Journal article
Feng N. et al, (2026), Molecular Therapy, 34, 1652 - 1671
Design, validation, and functional impact of oligonucleotides for multigene silencing in Alzheimer's disease.
Journal article
Woffindale C. et al, (2026), Molecular therapy. Nucleic acids, 37
Timing matters: exon skipping therapy is most effective when initiated early in a mouse model of Duchenne muscular dystrophy
Preprint
Stenler S. et al, (2025)
Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy
Journal article
Moschovaki-Filippidou F. et al, (2025), Brain, 148, 4495 - 4507
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy
Journal article
Chwalenia K. et al, (2025), Journal of Muscle Research and Cell Motility, 46, 293 - 300